Cancer of the Cervix, Cervical Cancer
Conditions
Brief summary
The investigators have developed co-registered transvaginal photoacoustic and ultrasound (US) imaging techniques that allow them to visualize ovarian tumor structure and functional changes simultaneously, which may potentially reveal early tumor angiogenesis development or residual tumors after systemic treatment that is not available by US alone. The ability to detect early angiogenesis changes, as well as tumor morphology changes using a non-invasive imaging modality will greatly enhance the care for patients. The investigators plan to explore these techniques in monitoring cervical cancer treatment response and conduct pilot feasibility studies.
Interventions
DEVICETransvaginal probe using photoacoustic and ultrasound imaging
-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of cervical cancer of any stage that will be treated with radiation therapy and concurrent chemotherapy. * At least 18 years of age. * Not pregnant and/or breastfeeding. * Able to understand and willing to sign an IRB-approved written informed consent document.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants who complete the imaging protocol | Approximately 18 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction rate of tumor angiogenesis | 3 months after completion of standard of care treatment (approximately 18 weeks) | * The reduction rate of tumor angiogenesis of clinical responders and non-responders will be analyzed * Responders and non-responders will be determined by standard of care PET imaging based on F18-FDG uptake, 3 months after completion of treatment |
| Charge pattern of blood oxygen saturation | 3 months after completion of standard of care treatment (approximately 18 weeks) | * The charge pattern of blood oxygen saturation of clinical responders and non-responders will be analyzed * Responders and non-responders will be determined by standard of care PET imaging based on F18-FDG uptake, 3 months after completion of treatment |
Countries
United States
Outcome results
None listed